Latest News

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

Long-acting injectable HIV treatments demonstrate clinical promise but face coverage and implementation barriers.

ADAP coverage gaps for long-acting injectable HIV treatments and equity implications.

Major HIV research breakthroughs from CROI 2024: long-acting treatments and prevention advances.

European Commission approves lenacapavir, a novel six-month injectable for treatment-resistant HIV.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.